Different Innovative UV-spectroscopic Approaches for Simultaneous Assessment of Celecoxib and Tramadol Hydrochloride in Binary Mixture

Background and Aim: Tablets containing celecoxib and tramadol hydrochloride that are sold under the brand name Seglentis® have given approval by the “Food and Drug Administration” (FDA) for the treatment of adults suffering from acute pain. Simultaneous assessment of celecoxib and tramadol hydrochloride in synthetic mixture was performed by five new UV-spectrophotometric approaches. Materials and Methods: The quantification of proposed medication was performed using the simultaneous equation approach by measuring absorbance at 217.2 and 272.4 nm. The second approach, known as the dual wavelength method, relies on computing the absorbance difference at two different wavelengths where the other drug has same absorbance. The first derivative zero crossing approach relied on the conversion of UV-spectra into first derivative spectra and subsequently measuring the amplitude at 272.4 and 229.6 nm for celecoxib and tramadol hydrochloride, respectively. The ratio difference approach was used to measure the variation in the amplitudes of ratio spectra, and the regression equation was employed to determine the amounts of pharmaceuticals. In first derivative ratio spectra approach, the UV-spectra were transformed into their ratio spectra and first derivatives, and the first-derivative signal was gauged at 236.4 and 229.8 nm for celecoxib and tramadol hydrochloride, sequentially. Results and Discussion: All the parameters were evaluated during validation of the new methods in accordance with ICH guidelines. For both medicines, a linear response was observed in all five methods over the concentration series of 1-18 µg/mL. Method validation parameters were found to be within the permitted limits set forth by the ICH. Conclusion: Assay results were compared using Repeated Measures ANOVA, IBM SPSS, version 20.0. The findings of the statistical analysis demonstrated that none of the projected methods differed significantly from others. Thus, the anticipated approaches have the potential to be productively utilized for the simultaneous evaluation of celecoxib and tramadol hydrochloride in a combination mixture.